Meghan Thompson, Memorial Sloan Kettering Cancer Center, New York, NY, talks on the impact of venetoclax on the chronic lymphocytic leukemia (CLL) treatment landscape, highlighting key trials including the MURANO trial (NCT02005471) and the CLL14 trial (NCT02242942). Dr Thompson discusses the retreatment of patients with CLL, in particular in patients who responded well to initial venetoclax treatment, and outlines growing evidence in favor of venetoclax retreatment. Five-year follow-up data from the MURANO trial reported that of 18 patients evaluable for response assessment following venetoclax retreatment, there was an overall response rate of 72%. Dr Thompson also shares data from a multi-center retrospective study which analyzed data from 25 heavily pretreated patients with CLL who had undergone venetoclax retreatment. Of 18 evaluable patients, the overall response rate was also 72%. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

свернуть